William Blair Has Negative Outlook for WST Q3 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) - Equities research analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for West Pharmaceutical Services in a research report issued to clients and investors on Friday, April 25th. William Blair analyst M. Larew now forecasts that the medical instruments supplier will earn $1.60 per share for the quarter, down from their prior forecast of $1.68. The consensus estimate for West Pharmaceutical Services' current full-year earnings is $6.62 per share. William Blair also issued estimates for West Pharmaceutical Services' Q4 2025 earnings at $1.69 EPS, Q1 2026 earnings at $1.59 EPS, Q2 2026 earnings at $1.74 EPS, Q3 2026 earnings at $1.83 EPS and Q4 2026 earnings at $1.93 EPS.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical instruments supplier reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.23. The firm had revenue of $698.00 million during the quarter, compared to analysts' expectations of $685.24 million. West Pharmaceutical Services had a net margin of 17.03% and a return on equity of 18.60%. West Pharmaceutical Services's revenue was up .4% compared to the same quarter last year. During the same period last year, the business earned $1.56 earnings per share.

Several other equities analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating and set a $250.00 price target for the company in a research note on Friday, February 14th. StockNews.com downgraded West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Thursday, February 27th. KeyCorp decreased their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Evercore ISI started coverage on shares of West Pharmaceutical Services in a research note on Tuesday, March 18th. They set an "outperform" rating and a $275.00 target price on the stock. Finally, Stephens raised shares of West Pharmaceutical Services to a "strong-buy" rating in a research report on Monday, April 21st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $332.50.

West Pharmaceutical Services Trading Down 1.3 %

Shares of WST traded down $2.78 during midday trading on Monday, hitting $213.34. 649,161 shares of the stock were exchanged, compared to its average volume of 720,329. The stock has a fifty day simple moving average of $218.37 and a 200 day simple moving average of $282.71. West Pharmaceutical Services has a 52-week low of $187.43 and a 52-week high of $372.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79. The firm has a market cap of $15.42 billion, a P/E ratio of 31.89, a P/E/G ratio of 6.74 and a beta of 1.22.

Institutional Investors Weigh In On West Pharmaceutical Services

Large investors have recently modified their holdings of the company. Whipplewood Advisors LLC purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at about $25,000. Retirement Wealth Solutions LLC purchased a new position in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $34,000. Centricity Wealth Management LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $35,000. Cornerstone Planning Group LLC grew its position in West Pharmaceutical Services by 57.1% in the 4th quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 40 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of West Pharmaceutical Services by 85.0% in the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier's stock worth $41,000 after acquiring an additional 85 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's payout ratio is currently 13.19%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.